Clinical Trials
20 trialsNCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT03781986 2026-03-03
APG-115 in Salivary Gland Cancer Trial
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT03556228 2025-12-11
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1/2 Recruiting
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT02538510 2024-11-26
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
University of Washington
Phase 1/2 Completed
NCT03749460 2023-12-29
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
Phase 1/2 Completed
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT05898373 2023-06-12
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
Peking Union Medical College
Phase 1/2 Not yet recruiting
NCT01816984 2021-10-05
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
University of Chicago
Phase 1/2 Completed
NCT01469429 2020-02-20
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT01806675 2019-10-03
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
Phase 1/2 Completed
NCT02042885 2015-10-20
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Otsuka Novel Products GmbH
Phase 1/2 Terminated
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00003182 2013-12-04
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00003251 2013-12-04
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00055770 2013-11-25
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00057850 2013-02-11
BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00021047 2012-03-08
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01313390 2011-12-12
DORA
University College, London
Phase 1/2 Terminated